Pemetrexed in the treatment of selected solid tumors

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

The novel agent pemetrexed inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Significant activity has been seen in completed phase II trials of pemetrexed in non-small cell lung cancer and breast cancer. Pemetrexed is also active in combination with other agents such as gemcitabine, cisplatin, and carboplatin. In addition, this agent shows promising activity in bladder, head and neck, esophageal, renal, and cervical carcinomas. Preliminary results of studies in these tumor types are reviewed.

Original languageEnglish (US)
Pages (from-to)50-53
Number of pages4
JournalSeminars in Oncology
Volume29
Issue number2 SUPPL. 5
StatePublished - Jan 1 2002

Fingerprint

Pemetrexed
gemcitabine
Hydroxymethyl and Formyl Transferases
Breast Neoplasms
Neoplasms
Carboplatin
Non-Small Cell Lung Carcinoma
Cisplatin
Urinary Bladder
Neck
Head
Carcinoma
Kidney

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Pemetrexed in the treatment of selected solid tumors. / Adjei, Alex.

In: Seminars in Oncology, Vol. 29, No. 2 SUPPL. 5, 01.01.2002, p. 50-53.

Research output: Contribution to journalReview article

@article{e7c32966376443d8959193740b62e5fd,
title = "Pemetrexed in the treatment of selected solid tumors",
abstract = "The novel agent pemetrexed inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Significant activity has been seen in completed phase II trials of pemetrexed in non-small cell lung cancer and breast cancer. Pemetrexed is also active in combination with other agents such as gemcitabine, cisplatin, and carboplatin. In addition, this agent shows promising activity in bladder, head and neck, esophageal, renal, and cervical carcinomas. Preliminary results of studies in these tumor types are reviewed.",
author = "Alex Adjei",
year = "2002",
month = "1",
day = "1",
language = "English (US)",
volume = "29",
pages = "50--53",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 5",

}

TY - JOUR

T1 - Pemetrexed in the treatment of selected solid tumors

AU - Adjei, Alex

PY - 2002/1/1

Y1 - 2002/1/1

N2 - The novel agent pemetrexed inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Significant activity has been seen in completed phase II trials of pemetrexed in non-small cell lung cancer and breast cancer. Pemetrexed is also active in combination with other agents such as gemcitabine, cisplatin, and carboplatin. In addition, this agent shows promising activity in bladder, head and neck, esophageal, renal, and cervical carcinomas. Preliminary results of studies in these tumor types are reviewed.

AB - The novel agent pemetrexed inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Significant activity has been seen in completed phase II trials of pemetrexed in non-small cell lung cancer and breast cancer. Pemetrexed is also active in combination with other agents such as gemcitabine, cisplatin, and carboplatin. In addition, this agent shows promising activity in bladder, head and neck, esophageal, renal, and cervical carcinomas. Preliminary results of studies in these tumor types are reviewed.

UR - http://www.scopus.com/inward/record.url?scp=0036264671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036264671&partnerID=8YFLogxK

M3 - Review article

VL - 29

SP - 50

EP - 53

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2 SUPPL. 5

ER -